China Sparsentan Active Pharmaceutical Ingredient Suppliers and Factory for High-Quality Pharmaceutical Solutions
Basic Information
Treatment of rare renal disorders, including focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), characterized by proteinuria and progressive loss of kidney function.
Dual Inhibition: Simultaneously blocks ETA receptors (reducing vasoconstriction, inflammation, and fibrosis) and AT1 receptors (lowering blood pressure and glomerular pressure).
Synergistic Effect: Combats pathogenic pathways in rare glomerular diseases by reducing proteinuria, preserving podocyte integrity, and delaying renal fibrosis.
Proven to significantly reduce proteinuria (up to 40–50% in clinical trials) compared to single-target therapies.
Demonstrated renal protective effects, slowing the progression to end-stage renal disease (ESRD).
| Dosage Forms | Film-coated tablets (e.g., 200 mg, 400 mg strengths). |
| Pharmacokinetics |
High oral bioavailability with linear absorption. Metabolized primarily via hepatic CYP450 enzymes (CYP3A4/5, CYP2C8). |
| Storage | Store at controlled room temperature (20–25°C), protected from moisture and light. |
| Shelf Life | 24 months under recommended storage conditions. |
Granted Orphan Drug Designation (ODD) and Fast Track status by the FDA for FSGS/IgAN.
Well-tolerated in trials; common adverse effects include peripheral edema, hypotension, and hyperkalemia (managed via dose adjustment).
Regular renal function and electrolyte assessments recommended during therapy.
Sparsentan represents a paradigm shift in rare nephrology by addressing dual pathogenic pathways with a single molecule. Its precision-engineered design ensures potent efficacy in reducing proteinuria and preserving renal function, offering hope for patients with limited treatment options. Backed by rigorous clinical evidence and robust manufacturing standards, Sparsentan is positioned as a breakthrough therapy for debilitating glomerular diseases.